Tolerability and Efficacy of Adjuvant T-DM1 in Patients With HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study
Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.
- EligibilityCriteria: Inclusion Criteria:  Histological diagnosis of HER2 positive breast cancer; Presence of invasive residual disease on T or N after neoadjuvant chemotherapy including anti-HER2 agents Treatment with T-DM1 in the adjuvant post-neoadjuvant setting, in case of positive hormone receptors in combination with adjuvant hormone therapy. Complementary radiotherapy will be allowed as per lines guide; Availability of adequate information regarding treatment with adjuvant T-DM1 in accordance with the objectives of the study; Written informed consent for the prospective part and, if possible, for the recruited patients retrospectively  Exclusion Criteria:  Concomitant treatments with other biological agents; Absence of clinical data that allow the correct analysis of the primary and secondary objectives; Patients with a history of other malignant neoplasms; Contraindications to the use of T-DM - HealthyVolunteers: No - Gender: Female - StdAgeList: Child, Adult, Older Adult - StudyPopulation: HER2 positive breast cancer - SamplingMethod: Non-Probability Sample